Cyclo Therapeutics (NASDAQ:CYTH) Trading Up 3% – Here’s What Happened

Cyclo Therapeutics, Inc. (NASDAQ:CYTH)’s share price shot up 3% on Monday . The stock traded as high as $0.73 and last traded at $0.72. 18,467 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 68,856 shares. The stock had previously closed at $0.70.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CYTH. Maxim Group restated a “hold” rating on shares of Cyclo Therapeutics in a report on Tuesday, August 27th. HC Wainwright reaffirmed a “neutral” rating and set a $0.95 target price (down from $3.00) on shares of Cyclo Therapeutics in a research report on Friday, August 23rd. Finally, Ascendiant Capital Markets dropped their target price on shares of Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating on the stock in a research report on Monday, August 26th.

Cyclo Therapeutics Stock Performance

The firm has a 50 day moving average of $0.72 and a 200-day moving average of $1.02. The stock has a market capitalization of $20.39 million, a PE ratio of -0.79 and a beta of -0.38.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.